ATE530174T1 - Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie - Google Patents

Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie

Info

Publication number
ATE530174T1
ATE530174T1 AT09720431T AT09720431T ATE530174T1 AT E530174 T1 ATE530174 T1 AT E530174T1 AT 09720431 T AT09720431 T AT 09720431T AT 09720431 T AT09720431 T AT 09720431T AT E530174 T1 ATE530174 T1 AT E530174T1
Authority
AT
Austria
Prior art keywords
allodynia
beta
treatment
field
chronic
Prior art date
Application number
AT09720431T
Other languages
English (en)
Inventor
Michel Barrot
Ipek Yalcin
Marie-Jose Freund-Mercier
Malika Benbouzid
Nada Choucair-Jaafar
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0800273A external-priority patent/FR2926464B1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE530174T1 publication Critical patent/ATE530174T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT09720431T 2008-01-18 2009-01-16 Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie ATE530174T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0800273A FR2926464B1 (fr) 2008-01-18 2008-01-18 Composes utilisables pour le traitement de douleurs neuropathiques
EP08003458 2008-02-26
EP08291065 2008-11-14
PCT/FR2009/000045 WO2009112674A2 (fr) 2008-01-18 2009-01-16 Composes utilisables pour le traitement de douleurs neuropathiques

Publications (1)

Publication Number Publication Date
ATE530174T1 true ATE530174T1 (de) 2011-11-15

Family

ID=41065598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09720431T ATE530174T1 (de) 2008-01-18 2009-01-16 Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie

Country Status (7)

Country Link
US (1) US20110027352A1 (de)
EP (1) EP2252278B1 (de)
JP (1) JP2011509981A (de)
AT (1) ATE530174T1 (de)
CA (1) CA2715110A1 (de)
ES (1) ES2375924T3 (de)
WO (1) WO2009112674A2 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3569592D1 (en) 1984-11-05 1989-05-24 Karl Vollenweider Connection joint for mainly semi-hollow and hollow section profiles
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
ATE494904T1 (de) * 2002-11-20 2011-01-15 Neuronova Ab Verbindungen und verfahren zur erhöhung der neurogenese
US7474933B2 (en) 2003-07-14 2009-01-06 Esilicon Corporation System and method for automating integration of semiconductor work in process updates
US7550466B2 (en) * 2003-08-27 2009-06-23 Sun Health Research Institute Alpha and/or β-adrenergic antagonists and agonists to treat pain
US7462618B2 (en) * 2003-08-27 2008-12-09 Sun Health Research Institute Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
EP1725226A2 (de) * 2004-03-17 2006-11-29 Sosei R&D Ltd. Behandlung von entzündlichen erkrankungen und schmerz mit beta-aminalkoholen
WO2006027579A2 (en) * 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
WO2006054513A1 (ja) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
GB0513297D0 (en) * 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
WO2007025613A2 (en) * 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain

Also Published As

Publication number Publication date
EP2252278A2 (de) 2010-11-24
JP2011509981A (ja) 2011-03-31
WO2009112674A3 (fr) 2009-12-10
ES2375924T3 (es) 2012-03-07
WO2009112674A2 (fr) 2009-09-17
EP2252278B1 (de) 2011-10-26
US20110027352A1 (en) 2011-02-03
CA2715110A1 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
PH12013501790B1 (en) Use of dpp iv inhibitors
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
MX338512B (es) Dispositivo para tratamiento médico y/o cosmético.
MY156285A (en) Co-crystals of tramadol and coxibs
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
DK1656122T4 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
BR112012006010A2 (pt) composto de glicina
IN2012DN04918A (de)
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EP2490700A4 (de) Externe hautzusammensetzung mit einem salz und einem zucker als wirkstoffen zur prophylaxe und behandlung von vaginose und verwendung davon
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
ATE530174T1 (de) Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties